Chemomab Therapeutics Ltd. Logo

Chemomab Therapeutics Ltd.

Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.

CMMB | US

Overview

Corporate Details

ISIN(s):
US16385C1045 (+1 more)
LEI:
Country:
United States of America
Address:
KIRYAT ATIDIM, BUILDING 7, 6158002 TEL AVIV
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's approach is centered on its discovery of the soluble protein CCL24 as a key driver of the vicious cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class, dual-activity monoclonal antibody designed to bind to and neutralize CCL24. Nebokitug has demonstrated disease-modifying potential and a favorable safety profile in multiple clinical trials for severe fibrotic diseases. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial in primary sclerosing cholangitis (PSC), for which nebokitug has received FDA Fast Track and Orphan Drug designations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chemomab Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemomab Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chemomab Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Mersana Therapeutics, Inc. Logo
Developing innovative antibody-drug conjugates using proprietary platforms to treat cancer.
United States of America
MRSN
Merus N.V. Logo
Develops multispecific antibody therapies that harness the immune system to fight cancer.
United States of America
MRUS
MESOBLAST LTD Logo
Develops off-the-shelf cellular medicines for complex inflammatory and chronic diseases.
United States of America
MESO
Metagenomi, Inc. Logo
Discovering novel gene editing tools from nature for curative genetic medicines.
United States of America
MGX
MetaVia Inc. Logo
A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.
United States of America
MTVA
Metsera, Inc. Logo
Develops potent, long-acting oral & injectable therapies for obesity & metabolic diseases.
United States of America
MTSR
Mezzion Pharma Co., Ltd. Logo
Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.
South Korea
140410
MFC Co., Ltd. Logo
A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.
South Korea
432980
Milestone Pharmaceuticals Inc. Logo
Developing a self-administered nasal spray for at-home treatment of acute cardiac events.
United States of America
MIST
MIMEDX GROUP, INC. Logo
Provides placental-based biologics for advanced wound care, surgical, and burn applications.
United States of America
MDXG

Talk to a Data Expert

Have a question? We'll get back to you promptly.